Submitted:
14 May 2026
Posted:
15 May 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Methodology
2.1. Study Design
- infection;
- latent disease progression;
- treatment initiation;
- treatment response and recovery; and
- the emergence and amplification of drug resistance during treatment.
- transmission rate (β);
- treatment initiation rate (γ); and
- resistance amplification rate (α).
- health-seeking behaviour;
- treatment adherence;
- healthcare accessibility;
- community trust;
- stigma reduction;
- and continuity of care.
2.2. Whole-Genome Sequencing Analysis
2.3. Identification of Potential Transmission Clusters
2.4. Transmission Model
- Susceptible individuals (S)
- Latent infection with DS and DR strains (Eₛ, Eᵣ)
- Infectious disease with DS and DR strains (Iₛ, Iᵣ)
- Individuals on treatment (Tₛ, Tᵣ)
- Recovered individuals (Rₛ, Rᵣ)
2.5. Integration of CBPR
- Partnership development and trust-building with community stakeholders
- Co-identification of barriers to TB prevention, diagnosis, and treatment
- Co-design of context-specific intervention strategies
- Collaborative interpretation of findings
- Action-oriented implementation and feedback
- Reduction in transmission rates (β) through improved infection prevention behaviors and reduced exposure.
- Increase in treatment initiation rates (γ) driven by earlier care-seeking and improved access to services
- Reduction in resistance amplification (α) through enhanced treatment adherence and continuity of care
2.6. Simulation of Community-Engaged Health Literacy Interventions
- Reduced transmission rates (βₛ, βᵣ), reflecting improved infection prevention practices and decreased exposure risk
- Increased treatment initiation rates (γₛ, γᵣ), associated with enhanced symptom recognition and timely healthcare utilization
- Reduced resistance amplification (α), resulting from improved adherence, treatment completion, and retention in care
- Baseline scenario: No community-based intervention
- Moderate CBPR intervention: Partial improvements in health literacy, care-seeking behavior, and treatment adherence
- High-intensity CBPR intervention: Substantial and sustained improvements driven by active community engagement and co-designed interventions
3. Results
3.1. Distribution of Drug-Sensitive and Drug-Resistant Strains
3.2. Lineage Distribution
3.3. Resistance-Associated Mutations
3.4. Evidence Suggestive of Resistant Strain Transmission
3.5. Mathematical Model Framework for DS–DR TB Transmission
- S – Susceptible
- Eₛ – Latent drug-sensitive infection
- Iₛ – Infectious DS-TB
- Tₛ – Treatment for DS-TB
- Rₛ – Recovered DS-TB
- Eᵣ – Latent drug-resistant infection
- Iᵣ – Infectious DR-TB
- Tᵣ – Treatment for DR-TB
- Rᵣ – Recovered DR-TB
- βₛ Iₛ / N – force of infection for DS strain
- βᵣ Iᵣ / N – force of infection for DR strain
- σₛ, σᵣ – progression from latent to active TB
- γₛ, γᵣ – treatment initiation rates
- ρₛ, ρᵣ – recovery rates
- α – resistance amplification during DS treatment
3.6. Resistance Evolution Pathway
3.7. Modeling the Impact of Community-Engaged TB Health Literacy on Transmission
- Earlier diagnosis and treatment initiation
- Improved treatment adherence
- Reduced transmission through behavioral awareness
3.8. Parameter Pathways Affected by Health Literacy
3.9. Predicted Epidemiological Impact
3.9.1. Reduction in Basic Reproduction Number
3.9.2. Shorter Infectious Period
3.9.3. Reduction in MDR Emergence
3.10. Simulation Scenario: Health Literacy Intervention
3.11. Mechanism of Community Engagement in the Model
3.12. Integration with the Socio-Ecological Model
3.13. Policy Implications
3.14. Modeling the Impact of Community-Engaged TB Health Literacy on Transmission
3.15. Impact of Community TB Education on Transmission Dynamics
4. Discussion
4.1. Role of Community-Based Participatory Research (CBPR) in Tuberculosis Transmission Dynamics
4.1.1. Conceptual Integration: From Health Literacy to Participatory Systems Change
4.2. CBPR as a Mechanism for Modifying Transmission Parameters
4.2.1. Transmission Rate (β): Socially Mediated Reduction
4.2.2. Treatment Initiation Rate (γ): Trust-Driven Acceleration
4.2.3. Resistance Amplification (α): Behavioral Control of Evolution
4.3. CBPR Process Model Applied to TB Transmission
| CBPR Phase | Transmission Relevance |
| Partnership & Trust Building | Improves healthcare engagement → reduces diagnostic delay |
| Co-identification of Problems | Identifies real drivers of transmission (e.g., under-testing of men) |
| Co-design of Interventions | Ensures context-specific strategies → increases uptake |
| Collaborative Data Collection | Enhances reach and surveillance quality |
| Co-analysis | Integrates lived experience into epidemiological interpretation. |
| Action & Intervention | Implements targeted transmission-reduction strategies |
| Dissemination | Improves community awareness and sustained behavior change |
| Reflection & Sustainability | Ensures long-term transmission control |
4.4. Methodological Implications: CBPR as Research Orientation
4.5. CBPR Within a Transdisciplinary TB Control Framework
4.6. Impact Pathway: Linking CBPR to Transmission Reduction
4.7. Integration with Genomic Surveillance and Modeling
4.8. Policy and Public Health Implications
5. Study Limitations
6. Recommendations
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviation
| AF | Allele Frequency |
| AIDS | Acquired Immunodeficiency Syndrome |
| AMPure XP | Agencourt AMPure XP Magnetic Beads |
| BWA | Burrows–Wheeler Aligner |
| CAS | Central Asian Strain |
| CBPR | Community-Based Participatory Research |
| DR-TB | Drug-Resistant Tuberculosis |
| DS-TB | Drug-Sensitive Tuberculosis |
| DNA | Deoxyribonucleic Acid |
| DOTS | Directly Observed Treatment, Short-course |
| GATK | Genome Analysis Toolkit |
| HIV | Human Immunodeficiency Virus |
| H37Rv | Mycobacterium tuberculosis Reference Strain |
| LTBI | Latent Tuberculosis Infection |
| MDR-TB | Multidrug-Resistant Tuberculosis |
| Mtb | Mycobacterium tuberculosis |
| PCR | Polymerase Chain Reaction |
| pre-XDR-TB | Pre-Extensively Drug-Resistant Tuberculosis |
| RR-TB | Rifampicin-Resistant Tuberculosis |
| SNP | Single-Nucleotide Polymorphism |
| TB | Tuberculosis |
| TDR-TB | Totally Drug-Resistant Tuberculosis |
| USAP | Unified Sequence Analysis Pipeline |
| WHO | World Health Organization |
| WGS | Whole-Genome Sequencing |
| XDR-TB | Extensively Drug-Resistant Tuberculosis |
References
- Farnia, P.; Velayati, A.A.; Ghanavi, J.; Farnia, P. Tuberculosis: An Ongoing Global Threat. In Proteins in Mycobacterium tuberculosis: Functions and Therapeutic Advances; Springer Nature Switzerland: Cham, 2025; pp. 1–31.
- Dheda, K.; Mirzayev, F.; Cirillo, D.M.; Udwadia, Z.; Dooley, K.E.; Chang, K.C.; Omar, S.V.; Reuter, A.; Perumal, T.; Horsburgh, C.R., Jr.; et al. Multidrug-Resistant Tuberculosis. Nat. Rev. Dis. Primers 2024,10, 22.
- Martínez-Zarazúa, C.; Cárdenas-Cuellar, M.J. Physiopathology of Extrapulmonary Tuberculosis: A Literature Review. Med. Stud. Res. J. 2023, 11, 1–1.
- Gilmour, B.; Alene, K.A. Ending Tuberculosis: Challenges and Opportunities. Front. Tuberc. 2024, 2, 1487518.
- Danchuk, S.N.; Solomon, O.E.; Kohl, T.A.; Dreyer, V.; Barilar, I.; Utpatel, C.; Niemann, S.; van Soolingen, D.; Anthony, R.; van Ingen, J.; et al. Challenging the Gold Standard: The Limitations of Molecular Assays for Detection of Mycobacterium tuberculosis Heteroresistance. Thorax 2024, 79, 670–675.
- Singh, A.; Prasad, R.; Balasubramanian, V.; Gupta, N. Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives. HIV/AIDS—Res. Palliat. Care 2020, 12, 9–31.
- Verma, A.; Singh, V.; Singh Chouhan, A.P.; Dutt, P.K. Tuberculosis: Symptoms, Diagnosis and the Fight against Drug Resistance. Biochem. Cell. Arch. 2024, 24.
- Al-Jardani, A.; Al Yaquobi, F.; Adikaram, C.; Al Wahaibi, A.; Al-Balushi, L.; Al-Zadjali, S.; Al Abri, B.; Al-Thuhli, K.; Al-Abri, S. Genomic and Geospatial Epidemiology of Mycobacterium tuberculosis in Oman: First National Insight Using Whole Genome Sequencing. Int. J. Infect. Dis. 2023, 130, S4–S11.
- Coleman, M.; Martinez, L.; Theron, G.; Wood, R.; Marais, B. Mycobacterium tuberculosis Transmission in High-Incidence Settings—New Paradigms and Insights. Pathogens 2022, 11, 1228.
- Roshdi Maleki, M. A Comprehensive Review of Genetic Mechanisms of Mycobacterium tuberculosis Resistance to Injectable Agents, Second-Line Drugs, and Novel Therapeutics. Infect. Drug Resist. 2026, 19, 1–22.
- Taha, M.M.; Abdelwahab, S.I.; Binjomah, A.Z.; Memish, Z.; Sahli, K.A.; Qadri, M.; Alarifi, A.; Khardali, A.; Farasani, A.; Madkhali, F.; et al. Mapping the Genomic Frontier: A Comprehensive Bibliometric Analysis and Thematic Evolution of Whole-Genome Sequencing for Mycobacterium tuberculosis (1994–2025). World J. Microbiol. Biotechnol. 2026, 42, 155.
- Naidoo, K.; Perumal, R.; Cox, H.; Mathema, B.; Loveday, M.; Ismail, N.; Omar, S.V.; Georghiou, S.B.; Daftary, A.; O’Donnell, M.; et al. The Epidemiology, Transmission, Diagnosis, and Management of Drug-Resistant Tuberculosis—Lessons from the South African Experience. Lancet Infect. Dis. 2024, 24, e559–e575.
- Mboowa, G. Reimagining Tuberculosis Control in the Era of Genomics: The Case for Global Investment in Mycobacterium tuberculosis Genomic Surveillance. Pathogens 2025, 14, 975.
- Negrete-Paz, A.M.; Vázquez-Marrufo, G.; Vázquez-Garcidueñas, M.S. Whole-Genome Comparative Analysis at the Lineage/Sublineage Level Discloses Relationships between Mycobacterium tuberculosis Genotype and Clinical Phenotype. PeerJ 2021, 9, e12128.
- Yin, J.; Zhang, H.; Gao, Z.; Jiang, H.; Qin, L.; Zhu, C.; Gao, Q.; He, X.; Li, W. Transmission of Multidrug-Resistant Tuberculosis in Beijing, China: An Epidemiological and Genomic Analysis. Front. Public Health 2022, 10, 1019198.
- Touray, B.J. Combating Persistent and Emerging Respiratory Pathogens through Innovative Nanovaccines. Ph.D. Thesis, University of Wisconsin-Madison, Madison, WI, USA, 2025.
- Said, H.; Ratabane, J.; Erasmus, L.; Gardee, Y.; Omar, S.; Dreyer, A.; Ismail, F.; Bhyat, Z.; Lebaka, T.; van der Meulen, M.; et al. Distribution and Clonality of Drug-Resistant Tuberculosis in South Africa. BMC Microbiol. 2021, 21, 157.
- Faye, L.M.; Hosu, M.C.; Apalata, T. Drug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Study of Patients’ Characteristics in Selected Healthcare Facilities. Int. J. Environ. Res. Public Health 2024, 21, 1594.
- Merker, M.; Rasigade, J.P.; Barbier, M.; Cox, H.; Feuerriegel, S.; Kohl, T.A.; Shitikov, E.; Klaos, K.; Gaudin, C.; Antoine, R.; et al. Transcontinental Spread and Evolution of Mycobacterium tuberculosis W148 European/Russian Clade toward Extensively Drug-Resistant Tuberculosis. Nat. Commun. 2022, 13, 5105.
- Kozhamkulov, U.; Iglikova, S.; Rakisheva, A.; Almazan, J. Multidrug-Resistant Tuberculosis in Central Asia and Predominant Beijing Lineage: Challenges in Diagnosis, Treatment Barriers, and Infection Control Strategies. Antibiotics 2025, 14, 673.
- Rodríguez-Grande, C.; Vallejo-Godoy, S.; Martínez-Lirola, M.; et al. Long-Term Refined Genomic Analysis of Tuberculosis Clusters to Distinguish between Ongoing Transmission, Reactivations or Diagnostic Delays, Almería, Spain, 2003 to 2024. Euro Surveill. 2026, 31, 2500301.
- Peter, O.J.; Abidemi, A.; Fatmawati, F.; Ojo, M.M.; Oguntolu, F.A. Optimizing Tuberculosis Control: A Comprehensive Simulation of Integrated Interventions Using a Mathematical Model. Math. Model. Numer. Simul. Appl. 2024, 4, 238–255.
- Nasrin, S.; Chowdhury, N.M. Dealing with Tuberculosis: Factors of Tuberculosis Medication Adherence among Marginalized Communities: A Scoping Literature Review. Int. J. Community Med. Public Health 2021, 8, 2544–2550.
- Khumalo, L.; Ellis, M.; Limson, J. A Relational Lens to Community-Based Participatory Research: An Analysis of Case Studies of Engaged Research in South Africa. S. Afr. J. Sci. 2026, 122, 1–8.
- Coll, F.; McNerney, R.; Preston, M.D.; Guerra-Assunção, J.A.; Warry, A.; Hill-Cawthorne, G.; Mallard, K.; Nair, M.; Miranda, A.; Alves, A.; et al. Rapid Determination of Anti-Tuberculosis Drug Resistance from Whole-Genome Sequences. Genome Med. 2015, 7, 51. [CrossRef]
- Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A Flexible Trimmer for Illumina Sequence Data. Bioinformatics 2014,30, 2114–2120. [CrossRef]
- Li, H.; Durbin, R. Fast and Accurate Long-Read Alignment with Burrows–Wheeler Transform. Bioinformatics 2010, 26, 589–595. [CrossRef]
- Ponstingl, H.; Ning, Z. SMALT—A New Mapper for DNA Sequencing Reads. F1000Posters 2010, 1, 313.
- Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; Abecasis, G.; Durbin, R.; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map Format and SAMtools. Bioinformatics 2009, 25, 2078–2079. [CrossRef]
- McKenna, A.; Hanna, M.; Banks, E.; Sivachenko, A.; Cibulskis, K.; Kernytsky, A.; Garimella, K.; Altshuler, D.; Gabriel, S.; Daly, M.; et al. The Genome Analysis Toolkit: A MapReduce Framework for Analyzing Next-Generation DNA Sequencing Data. Genome Res. 2010, 20, 1297–1303. [CrossRef]
- Liebenberg, D.; Gordhan, B.G.; Kana, B.D. Drug-Resistant Tuberculosis: Implications for Transmission, Diagnosis, and Disease Management. Front. Cell. Infect. Microbiol. 2022, 12, 943545.
- Dekhil, N.; Mardassi, H. Genomic Changes Underpinning the Emergence of a Successful Mycobacterium tuberculosis Latin American and Mediterranean Clonal Complex. Front. Microbiol. 2023, 14, 1159994.
- Atavliyeva, S.; Auganova, D.; Tarlykov, P. Genetic Diversity, Evolution and Drug Resistance of Mycobacterium tuberculosis Lineage 2. Front. Microbiol. 2024, 15, 1384791.
- Klopper, M.; Heupink, T.H.; Hill-Cawthorne, G.; Streicher, E.M.; Dippenaar, A.; De Vos, M.; Abdallah, A.M.; Limberis, J.; Merker, M.; Burns, S.; et al. A Landscape of Genomic Alterations at the Root of a Near- Untreatable Tuberculosis Epidemic. BMC Med. 2020,18, 24. [CrossRef]
- Faye, L.M.; Hosu, M.C.; Vasaikar, S.; Dippenaar, A.; Oostvogels, S.; Warren, R.M.; Apalata, T. Spatial Distribution of Drug-Resistant Mycobacterium tuberculosis Infections in Rural Eastern Cape Province of South Africa. Pathogens 2023, 12, 475. [CrossRef]
- Conceição, E.C.; Loubser, J.; Guimarães, A.E.D.S.; Sharma, A.; Rutaihwa, L.K.; Dippenaar, A.; Salvato, R.S.; de Paula Souza e Guimarães, R.J.; da Silva Lourenço, M.C.; Barros, W.A.; et al. A Genome-Focused Investigation Reveals the Emergence of a Mycobacterium tuberculosis Strain Related to Multidrug-Resistant Tuberculosis in the Amazon Region of Brazil. Microorganisms 2024,12, 1817. [CrossRef]
- Chizimu, J.Y.; Solo, E.S.; Bwalya, P.; Tanomsridachchai, W.; Chambaro, H.; Shawa, M.; Kapalamula, T.F.; Lungu, P.; Fukushima, Y.; Mukonka, V.; et al. Whole-Genome Sequencing Reveals Recent Transmission of Multidrug-Resistant Mycobacterium tuberculosis CAS1-Kili Strains in Lusaka, Zambia. Antibiotics 2021, 11, 29. [CrossRef]
- World Health Organization (WHO). Global Tuberculosis Report 2023; World Health Organization: Geneva, Switzerland, 2023. Available online: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023 (accessed on 10 May 2026).
- Lan, Y.; Rancu, I.; Chitwood, M.H.; Sobkowiak, B.; Nyhan, K.; Lin, H.H.; Wu, C.Y.; Mathema, B.; Brown, T.S.; Colijn, C.; et al. Integrating Genomic and Spatial Analyses to Describe Tuberculosis Transmission: A Scoping Review. Lancet Microbe 2025, 6, 101094. [CrossRef]
- Smith, J.P.; Cohen, T.; Dowdy, D.; Shrestha, S.; Gandhi, N.R.; Hill, A.N. Quantifying Mycobacterium tuberculosis Transmission Dynamics across Global Settings: A Systematic Analysis. Am. J. Epidemiol. 2023, 192, 133–145.
- Mboowa, G. Reimagining Tuberculosis Control in the Era of Genomics: The Case for Global Investment in Mycobacterium tuberculosis Genomic Surveillance. Pathogens 2025, 14, 975.
- Smith, J.P.; Cohen, T.; Dowdy, D.; Shrestha, S.; Gandhi, N.R.; Hill, A.N. Quantifying Mycobacterium tuberculosis Transmission Dynamics across Global Settings: A Systematic Analysis. Am. J. Epidemiol. 2023, 192, 133–145.
- Chavez-Rimache, L.; Ugarte-Gil, C.; Brunette, M.J. The Community as an Active Part in the Implementation of Interventions to Prevent and Control Tuberculosis: A Scoping Review. medRxiv 2023.
- Lazarus, S.; Naidoo, A.V.; May, B.; Williams, L.; Demas, G.; Filander, F.J. Lessons Learnt from a Community-Based Participatory Research Project in a South African Rural Context. S. Afr. J. Psychol. 2014, 44, 149–161.
- Riccardi, M.T.; Pettinicchio, V.; Di Pumpo, M.; Altamura, G.; Nurchis, M.C.; Markovic, R.; Šagrić, Č.; Stojanović, M.; Rosi, L.; Damiani, G. Community-Based Participatory Research to Engage Disadvantaged Communities: Levels of Engagement Reached and How to Increase It: A Systematic Review. Health Policy 2023, 137, 104905.
- Moore, T.R.; Chusan, Y.A.; Sanderson, E.; Calancie, L.; Hennessy, E.; Appel, J.M.; Ulseth, M.; Economos, C.D. Community-Led Change: Progress toward Policy, Systems, and Environmental Impacts through the Catalyzing Communities Initiative. PLoS ONE 2025, 20, e0336482.
- Hayward, S.E.; Vanqa, N.; Makanda, G.; Tisile, P.; Ngwatyu, L.; Foster, I.; Mcinziba, A.A.; Biewer, A.; Mbuyamba, R.; Galloway, M.; et al. “As a Patient I Do Not Belong to the Clinic, I Belong to the Community”: Co-Developing Multi-Level, Person-Centered Tuberculosis Stigma Interventions in Cape Town, South Africa. BMC Glob. Public Health 2024, 2, 55.







Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.